Circulating circRNA in Acute Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
CRAST is to analyze the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.

Detailed Description
-----------------
Circular RNAs have been highlighted to be involved in the pathological process of ischemic stroke (IS). The purpose of this protocol will investigate the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke. Distinctive expression patterns of circRNA will be identified by individual quantitative real time polymerase chain reaction (qRT-PCR). A diagnostic or predictive model will be established using logistic regression. The panel of these altered circRNAs may be associated with acute IS and could serve as a novel diagnostic or predictive method.

Official Title
-----------------
Clinical Significance of Circulating circRNA in Acute Ischemic Stroke (CRAST)

Conditions
-----------------
Acute Ischemic Stroke

Intervention / Treatment
-----------------
* Genetic: Quantitative Real-time polymerase chain reaction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years or older Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan Within 72 hours of symptom onset Good performance status Signed an approved informed consents Exclusion Criteria: a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AIS group<br>This group includes patients with acute ischemic stroke (AIS). | Genetic: Quantitative Real-time polymerase chain reaction<br>* Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).<br>|
| HC group<br>This group includes healthy controls (HC). | Genetic: Quantitative Real-time polymerase chain reaction<br>* Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differential expression pattern of circRNA | Differential expression pattern of circular RNA (circRNA) will be compared between AIS group and HC group, thus candidate circRNA will be verified as biomarkers for the detection and prognosis of AIS. | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dynamic changes of circRNA during the follow-up period | Dynamic changes of circRNA will be explored before and after endovascular therapy | 90 days | 
| Correlation of circRNA and stroke-associated infection | Correlation of circRNA and stroke-associated infection will be explored in acute ischemic stroke. | 30 days | 
| Correlation of circRNA and inflammatory factors in acute ischemic stroke | Correlation of circRNA and inflammatory factors on admission will be explored in acute ischemic stroke. | 7 days | 
| Prognostic value of circRNA in acute ischemic stroke | The prognosis of AIS patients will be analyzed between differential expressed candidate circRNA after they have completed the systematic therapy. | 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
circRNA